TipRanks
Go Ultimate55% OFF

Atossa Therapeutics (YAG) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
-EndoxifenPrecocious Puberty, Gonadotropin-DependentPhase IINot Yet Recruiting(Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious PubertyOct 06, 2026―
Goserelin, -EndoxifenBreast Neoplasms, Her2-Negative Breast Cancer, Invasive Breast Cancer, Estrogen-Receptor-Positive Breast CancerPhase IIActive Not Recruiting(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerOct 26, 2022
Z-EndoxifenBreast DensityPhase IICompletedEffect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast DensitySep 27, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Atossa Therapeutics, Inc. (DE:YAG) have in its pipeline
Atossa Therapeutics DE:YAG is currently developing the following drugs: -Endoxifen, Goserelin, -Endoxifen, Z-Endoxifen. These drug candidates are in various stages of clinical development as the company works toward FDA approval.